Effects of GLP-1 Receptor Agonists on Saliva and Oral Health

NCT07818226 | Not Yet Recruiting

• 2 other identifiers: 2026.06.372026/142
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the effects of GLP-1 receptor agonists (GLP-1RA) on salivary parameters and oral health in individuals who will use this medication for the first time due to a diagnosis of Type 2 diabetes and/or obesity. The research will be conducted with a longitudinal design including a total of 50 participants. Clinical examinations and saliva analyses will be performed at baseline (month 0), month 3, and month 6. The study will evaluate stimulated and unstimulated salivary flow rates, pH, and buffering capacity, as well as analyze antimicrobial peptide levels (sIgA and beta-defensin-3) and total protein. Participants' oral hygiene and caries activity will be measured using the Silness and Löe Plaque Index (PI), DMFT, and ICDAS-II indices. Additionally, dietary habits and subjective dry mouth symptoms will be monitored through questionnaires. The obtained data will be statistically analyzed by controlling for potential confounding factors such as HbA1c, BMI, CRP, and HOMA index.

Conditions

Type 2 Diabetes; Obesity & Overweight; Xerostomia; Dental Caries

Outcome Measures

Primary Outcomes (1)

• Change in Unstimulated Salivary Flow Rate

  According to the GC Saliva-Check Buffer kit (GC Corporation) instructions, following a visual inspection, unstimulated whole saliva will be collected via the passive drooling/spitting method for 5 minutes with the participant seated upright and head tilted slightly forward. The resting salivary flow rate will be calculated and reported in milliliters per minute (mL/min).

  Baseline (Month 0), Month 3, and Month 6

Secondary Outcomes (14)

• Change in Stimulated Salivary Flow Rate

  Baseline (Month 0), Month 3, and Month 6

• Change in Salivary pH

  Baseline (Month 0), Month 3, and Month 6

• Change in Salivary Buffering Capacity

  Baseline (Month 0), Month 3, and Month 6

• Change in Dental Plaque Accumulation

  Baseline (Month 0), Month 3, and Month 6

• Change in Dental Caries Status

  Baseline (Month 0), Month 3, and Month 6

Study Arms (1)

GLP-1 RA Group

Patients diagnosed with Type 2 diabetes and/or obesity who are newly prescribed GLP-1 receptor agonists.

Drug: GLP-1 Receptor Agonists

Interventions

GLP-1 Receptor Agonists DRUG

Patients diagnosed with Type 2 diabetes and/or obesity who are newly prescribed GLP-1 receptor agonists as part of their routine medical treatment. Baseline assessments are performed prior to the first dose, and no drug administration or dosage modification is performed by the researcher.

GLP-1 RA Group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients admitted to the clinic who are diagnosed with Type 2 diabetes and/or obesity and are newly scheduled to initiate treatment with GLP-1 receptor agonists.

You may qualify if:

• Diagnosed with Type 2 Diabetes Mellitus and/or Obesity.
• Newly prescribed a GLP-1 receptor agonist and naive to GLP-1 receptor agonist therapy.
• Aged 18 to 65 years
• Willing to provide saliva samples and complete study questionnaires.

You may not qualify if:

• Presence of Sjögren's syndrome or known salivary gland disease.
• History of radiation therapy to the head and neck region.
• Use of antibiotic or antifungal medications within the last 3 months.
• Pregnancy, lactation, or active orthodontic treatment.
• Presence of other severe systemic diseases or use of medications that affect salivary flow.

Sponsors & Collaborators

• Kırıkkale University: lead

Study Sites (1)

Kirikkale University Faculty of Dentistry

Kirikkale, Yahsihan, 71450, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Obesity; Overweight; Xerostomia; Dental Caries

Interventions

Glucagon-Like Peptide-1 Receptor Agonists

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Salivary Gland Diseases; Mouth Diseases; Stomatognathic Diseases; Tooth Demineralization; Tooth Diseases

Intervention Hierarchy (Ancestors)

Hypoglycemic Agents; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses

Central Study Contacts

Merve Haberal, Assist. Prof. Dr.

CONTACT

+905366592335; mervehaberal@hotmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Restorative Dentistry

Study Record Dates

• First Submitted: September 2, 2026
• First Posted: September 14, 2026
• Study Start (Estimated): October 16, 2026
• Primary Completion (Estimated): July 16, 2027
• Study Completion (Estimated): December 15, 2027
• Last Updated: September 14, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)